SEC Company Response from Edesa Biotech, Inc. (EDSA) (CIK 0001540159) (EDSA) — May 9, 2018
Edesa Biotech, Inc. (EDSA) (CIK 0001540159)
Date: May 9, 2018 · CIK: 0001540159 · Accession: 0001144204-18-026390
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224314
Letter
Attention: Ada D. Sarmento and Suzanne Hayes Division of Corporation Finance Washington, D.C. 20549 RE: Stellar Biotechnologies, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File Number 333-224314
Dear Mses. Sarmento and Hayes:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the Registration Statement that such Registration Statement will become effective as of 5:00 P.M. on Thursday, May 10, 2018, or as soon thereafter as practicable.
The Company hereby acknowledges that:
· Should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority, declare the Registration Statement effective, the Commission is not foreclosed from taking any action with respect to the Registration Statement;
· The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
· The Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
STELLAR BIOTECHNOLOGIES, INC.
Show Raw Text
CORRESP
1
filename1.htm
Stellar Biotechnologies, Inc.
332 E. Scott Street
Port Hueneme, CA 93041
May 9, 2018
Unites States Securities and
Exchange Commission
Attention: Ada D. Sarmento and Suzanne Hayes
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
RE: Stellar Biotechnologies, Inc. (the “Company”)
Registration
Statement on Form S-1 (the “Registration Statement”)
File
Number 333-224314
Dear Mses. Sarmento and Hayes:
The Company hereby
requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of the effectiveness of the
Registration Statement that such Registration Statement will become effective as of 5:00 P.M. on Thursday, May 10, 2018, or as
soon thereafter as practicable.
The Company hereby acknowledges that:
· Should the Securities and Exchange Commission (the “Commission”) or the Staff, acting pursuant to delegated authority,
declare the Registration Statement effective, the Commission is not foreclosed from taking any action with respect to the Registration
Statement;
· The action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement
effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration
Statement; and
· The Company may not assert the declaration of effectiveness as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
STELLAR BIOTECHNOLOGIES, INC.
By:
/s/ Kathi Niffenegger
Name: Kathi Niffenegger
Title: Chief Financial
Officer